Table 3 IMP3 and p53 immunoreactivity in STIC and invasive HGSC
From: IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis
| Â | Â | Invasive HGSC of ovary | ||||
|---|---|---|---|---|---|---|
| Â | STIC | W/ STIC | W/O STIC | |||
| Â | No. (%) cases | P | No. (%) cases | P | No. (%) cases | P |
IMP3+ | 22 (46) | Â | 20 (42) | Â | 25 (40) | Â |
IMP3- | 26 (54) | 0.82 | 28 (58) | 0.56 | 37 (60) | 0.71 |
p53+ | 40 (83) | Â | 42 (88) | Â | 53 (85) | Â |
p53- | 8 (17) | < 0.01 | 6 (12) | < 0.01 | 9 (15) | < 0.01 |
IMP3+/p53+ | 17 (35) | Â | 17 (35) | Â | 19 (31) | Â |
IMP3+/p53- | 5 (10) | <0.05 | 3 (6) | <0.05 | 7 (11) | <0.05 |
IMP3-/p53+ | 18 (38) | Â | 20 (42) | Â | 28 (45) | Â |
IMP3-/p53- | 8 (17) | 0.26 | 8 (17) | 0.16 | 9 (15) | 0.08 |